正规澳门赌场网络教授获奖励1美元.7 million to study treatment for HIV nerve complications

曹玲，M.D., Ph.D., a professor of biomedical sciences in the University of New England’s College of 整骨疗法的医学他获得了1美元的奖金.7 million grant from the National Institutes of 健康 (NIH) to 研究 the development of a novel drug to alleviate nerve pain in more than half of HIV patients.

The funding will be distributed over a five-year span to support Cao’s 研究 to understand HIV-associated neuropathy further. This nerve-damaging condition often manifests as hard-to-treat pain and affects about half of the people living with HIV.

“With the advancement of antiretroviral treatment, people with HIV live longer and are more likely to experience HIV-associated chronic complications, such as HIV sensory neuropathy,曹说, “This condition occurs as the peripheral nerves are dying off over time. 结果是, 四肢, such as toes are likely to be affected first, followed by the limbs as it progresses. 临床, it is hard to distinguish HIV sensory neuropathy from other similar peripheral neuropathies.

目前，没有美国.S. Food and Drug Administration (FDA)-approved treatment for this condition, existing treatments aiming to manage the symptoms are not always effective. Cao said the NIH-funded 研究 enables her lab to make real contributions to eventual drug development. To do that, Cao will collaborate with Benjamin Harrison, Ph.D., assistant professor in the UNE Department of Biomedical 科学s, to study the neuropathy in animal models.

Cao has been studying HIV neuropathy since 2006, this particular 研究 phase has been underway since 2018. 多年来, many undergraduate and graduate students have been involved in her study and some of the previous results generated by students contributed to the grant application. The R01 federal grant money will allow Cao to continue recruiting and maintaining more student 研究ers to experience 研究 and be part of discoveries.

“We always involve students in our 研究. It's a part of UNE's mission for 研究 education for our students, helps UNE to make contributions to Maine’s biomedical 研究 future,曹说.

Cao hopes to be able to identify at least a couple of drug candidates by the time this 研究 concludes and to be able to move to the next phase of drug development, eventually clinical trials and FDA approval.

“We're talking many years and perhaps decades down the road,曹说. “But, that's definitely our dream.”